Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abciximab vs Eptifibatide vs Bivalirudin during PCI in Acute Coronary Syndromes
2009-009039-32Phase 4Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- Feb 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in acute ST-segment elevation myocardial infarction (STEMI), Non-ST-segment elevation myocardial infarction (NSTEMI), unstable angina and 1 more comparing Abciximab arm, Eptifibatide arm and Bivalirudin arm (3 arms). Primary endpoint: Platelet activation after PCI. Started Feb 2009; status: completed.
02
Drugs
abciximabeptifibatidebivalirudin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)Non-ST-segment elevation myocardial infarction (NSTEMI)unstable anginamyocardial infarction (MI)
Beyond the preview
Go deeper on 2009-009039-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009039-32.